For retail investors, it has only become possible to invest in startups and private companies over the last 1-2 decades. This is largely the result of new legislation like Regulation CF and the proliferation of startup investing platforms. Prior to this, only well-connected investors with a significant net worth had the opportunity to invest in these companies.

Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.

Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discuss OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

The investing world is rapidly evolving.

Healthcare provides another avenue in which investors can do well by doing good.

Bioverge recently invested in Enveda’s $51 million Series A led by Lux Capital.  Enveda is biotechnology startup focused on harnessing the power of nature’s chemistry to develop next generation small-molecule therapeutics.

Starton Therapeutics, a drug delivery biotech, is raising its next round of capital through Unicorn Hunters, a streaming show that invites viewers to consider and invest in a variety of startups alongside a panel of celebrity investors.

James Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.